Supplementary Table 1.docx (13.55 kB)
Download file

Supplementary Table 1: DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.

Download (13.55 kB)
dataset
posted on 06.05.2021, 09:20 by Cristobal Morales, Virginia Bellido, Cristina Tejera, Fernando Goñi, Rafael Palomares, Cristina Sevillano, Diego Bellido, Alfonso Soto, Miguel Ángel Mangas, Manuel A Botana, Irene Caballero

Supplementary Table 1. DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain.



Abstract

Background: Weight reduction and glycemic control are key goals during Type 2 diabetes (T2D) management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. Methods: DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in T2D patients in Spain. Results: The study population comprised 1,046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8±10.0 and 66.2±11.4 years and HbA1c 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. Conclusions: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.

Funding

This work was supported by AstraZeneca.

History